← Apogee Therapeutics, Inc. (APGE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Apogee Therapeutics, Inc. (APGE)
Biological Products, (No Diagnostic Substances) · market cap $1.8B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Apogee Therapeutics (APGE) is a clinical-stage biotech with 196 employees and a ~$1.76B market cap, built around APG777, a Phase 2 candidate for atopic dermatitis whose mechanism of action is not publicly disclosed in available filings. The company carries no revenue, a $452M cash position, and an estimated ~24-month runway, with the next major de-risking event being Phase 2 APG777 data expected around November 2026.
The catalyst path
- 2026-11-15 (est.)Phase 2 · APG777imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| APG777 | Phase 2 | Atopic Dermatitis |
Price & technical context
3-month
+64.4%
6-month
+93.0%
12-month
+257.4%
52-wk range
$36.37–$135.07
vs 50-day MA
+1.4%
vs 200-day MA
+48.6%
Realized vol
63.2%
Max drawdown
-52.9%
Daily closes through 2026-09-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APGE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.